Early findings of two studies from the University of Michigan Health Rogel Cancer Center shed light on new ways to anticipate recurrence in HPV-positive head and neck cancer sooner. The papers, published in Cancer and Oral Oncology, offer clinical and technological perspectives on how to measure if recurrence is happening earlier than current blood tests allow, and provide a framework for a new, more sensitive blood test that could help in this monitoring.
|
A study from the University of Michigan Department of Neurosurgery and Rogel Cancer Center shows promising early results that a therapy combining cell-killing and immune-stimulating drugs are safe and effective in extending survival for patients with gliomas, a highly aggressive form of brain cancer.
|
|
Using tissue samples and cell models from patients, Joshi Alumkal, M.D., Wicha Family Professor of Oncology and leader of the genitourinary medical oncology section at Rogel, and his team zeroed in on the lysine specific demethylase 1, a protein involved in turning genes off and on in normal and cancer cells that appears particularly important in certain aggressive forms of prostate cancer.
|
The findings show that the patients who had renal tumors with TFEB amplification were significantly older than patients with renal tumors housing TFE3 or TFEB translocation. Further, renal tumors with TFEB amplification, known to be associated with poor prognosis, were seen to be at least three times as common as those with TFEB translocation.
|
Every year, health plans offer open enrollment – a time to reassess your benefits and select new options. But is it worth the hassle to change plans? For people with expensive prescription drugs, switching plans could save them thousands of dollars in copays. And a simple tool can help people easily compare out-of-pockets expenses for anyone with a Medicare Part D prescription plan.
|
University of Michigan Health will purchase the Edison platform used to deliver histotripsy, a technology pioneered at the university that uses sound waves to destroy tissue. HistoSonics, a company co-founded by U-M faculty, received approval this week from the U.S. Food and Drug Administration to use histotripsy via the Edison platform in liver treatment.
|
The annual hospital review included the cancer center on their list of elite programs around the county.
|
For the first time, researchers have found a potential drug candidate that improved outcomes for patients with a type of childhood brain tumor for which there are no effective treatments. The compound, called ONC201, nearly doubled survival for patients with diffuse midline glioma or diffuse intrinsic pontine glioma, compared to previous patients.
|
An analysis finds that up to millions of dollars could be saved annually on cancer immunotherapy treatments across the Veterans Health Administration by reconsidering how those drugs are delivered.
|
|
|
MENU